These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 12906003

  • 1. American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
    Erlich R, Durrance A.
    IDrugs; 2003 Jul; 6(7):623-4. PubMed ID: 12906003
    [No Abstract] [Full Text] [Related]

  • 2. [Anti-angiogenic treatment and colorectal cancer].
    André T, Tournigand C, Abbas F, Louvet C, de Gramont A, Gercor (French Oncology Research Group).
    Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
    [Abstract] [Full Text] [Related]

  • 3. Future directions with angiogenesis inhibitors in colorectal cancer.
    Bilenker JH, Haller DG.
    Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S86-93. PubMed ID: 15479485
    [Abstract] [Full Text] [Related]

  • 4. Taming glioblastoma by targeting angiogenesis: 3 years later.
    Wong ET, Brem S.
    J Clin Oncol; 2011 Jan 10; 29(2):124-6. PubMed ID: 21135277
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Current role of bevacizumab in colorectal cancer.
    Saltz L.
    Clin Adv Hematol Oncol; 2009 Jun 10; 7(6):375-6. PubMed ID: 19606071
    [No Abstract] [Full Text] [Related]

  • 7. Bevacizumab: improved survival at what cost?
    Kolesar JM.
    Am J Health Syst Pharm; 2005 May 15; 62(10):1017. PubMed ID: 15901584
    [No Abstract] [Full Text] [Related]

  • 8. Challenges and pitfalls of combining targeted agents in phase I studies.
    Cannistra SA.
    J Clin Oncol; 2008 Aug 01; 26(22):3665-7. PubMed ID: 18669449
    [No Abstract] [Full Text] [Related]

  • 9. Risk of venous thromboembolism with bevacizumab in cancer patients.
    Cortes J, Saura C, Atzori F.
    JAMA; 2009 Apr 08; 301(14):1434-5; author reply 1435-6. PubMed ID: 19351936
    [No Abstract] [Full Text] [Related]

  • 10. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W, Weller M, van den Bent M, Stupp R.
    J Clin Oncol; 2010 Apr 20; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract] [Full Text] [Related]

  • 11. Bevacizumab in the treatment of ovarian cancer.
    Han ES, Monk BJ.
    Expert Rev Anticancer Ther; 2007 Oct 20; 7(10):1339-45. PubMed ID: 17944559
    [Abstract] [Full Text] [Related]

  • 12. [Novel molecular approaches in the therapy of advanced colorectal carcinoma].
    Vanhoefer U.
    Onkologie; 2003 Dec 20; 26 Suppl 7():70-4. PubMed ID: 14716146
    [Abstract] [Full Text] [Related]

  • 13. Bevacizumab for advanced breast cancer.
    Traina TA, Rugo HS, Dickler M.
    Hematol Oncol Clin North Am; 2007 Apr 20; 21(2):303-19. PubMed ID: 17512451
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.
    Uronis HE, Jia J, Bendell JC, Howard L, Ready NA, Lee PH, Starr MD, Dellinger A, Pang H, Nixon AB, Hurwitz HI.
    Cancer Chemother Pharmacol; 2015 Feb 20; 75(2):343-52. PubMed ID: 25527204
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T, Lindley C.
    Clin Ther; 2006 Nov 20; 28(11):1779-802. PubMed ID: 17212999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.